GlaxoSmithKline, (GSK) the
UK’s biggest drug maker, has been
fined more than £37.6m by the
Competition and Markets Authority
for arranging deals between 2001
and 2004 to reduce competition
from generic drug manufacturers
with its antidepressant paroxetine,
according to a report in the BMJ.
GSK’s branded version of
paroxetine, Seroxat, was one of
GSK’s best selling drugs, with sales
exceeding £90m.The above article was sent to subscribers in Pharmacy Daily's issue from 16 Feb 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Feb 16
RESPONDING to the findings from the Royal Commission into Aged Care Quality and Safety, a recent government initiative aims to improve medication management in residential aged care facilities by introducing on-site pharmacists.
RESEARCHERS at Charles Darwin University (CDU) are advancing a novel drug delivery system that could potentially eliminate the need for injections to treat various chronic diseases.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.